- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- February 2024
- 150 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- March 2024
- 238 Pages
Global
From €7686EUR$7,950USD£6,602GBP
- Report
- July 2023
- 284 Pages
Global
From €3480EUR$3,600USD£2,990GBP
- Report
- October 2023
- 270 Pages
China
From €3867EUR$4,000USD£3,322GBP
- Report
- October 2023
- 135 Pages
China
From €1740EUR$1,800USD£1,495GBP
- Report
- March 2019
- 239 Pages
Global
From €5192EUR$5,370USD£4,459GBP
Ceftazidime is a third-generation cephalosporin antibiotic used to treat a wide range of bacterial infections. It is a broad-spectrum antibiotic, meaning it is effective against a wide range of bacteria. Ceftazidime is commonly used to treat infections of the respiratory tract, urinary tract, skin, and soft tissue. It is also used to treat infections caused by certain types of bacteria that are resistant to other antibiotics. Ceftazidime is often used in combination with other antibiotics to treat more serious infections.
Ceftazidime is available in both injectable and oral forms. It is typically administered intravenously in a hospital setting, but can also be taken orally for certain infections. Ceftazidime is generally well tolerated, but can cause side effects such as nausea, vomiting, and diarrhea.
The market for Ceftazidime is highly competitive, with many companies offering their own versions of the drug. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, AstraZeneca, and Sanofi. Show Less Read more